{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:26:10Z","timestamp":1786987570505,"version":"build-2736575974"},"reference-count":51,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Science and Higher Education of the Russian Federation","award":["FZGU-2023-0009"],"award-info":[{"award-number":["FZGU-2023-0009"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>To develop efficient and structurally novel anticoagulants, a library of new hybrid molecules\u2014(Z)-1-(2-(4-arylthiazol-2-yl)hydrazineylidene)-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2-ones\u2014was designed and synthesized through a two-step approach. The reaction of pyrrolo[3,2,1-ij]quinoline-1,2-diones with thiosemicarbazide produced thiosemicarbazones, which were subsequently reacted with \u03b1-bromoacetophenones. The structure of the resulting compounds was determined by HPLC-HRMS-ESI analysis, 1H NMR spectroscopy, and 13C NMR spectroscopy. X-ray diffraction analysis unambiguously confirmed the structure of the resulting substances. The synthesized compounds were tested for their anticoagulant activity in vitro. Among the tested derivatives, two substances have a dual effect and exhibit 98\u2013100% inhibitory ability against blood coagulation factors Xa and XIa at 30 \u03bcM. IC50 values were also evaluated for these compounds. The results obtained show the high potential of the synthesized derivatives in the development of new multitarget anticoagulant drugs. The docking studies confirmed the experimental results.<\/jats:p>","DOI":"10.3390\/molecules30173544","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T16:18:15Z","timestamp":1756484295000},"page":"3544","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Design, Synthesis, and In Vitro and In Silico Study of New Hybrid 1-(2-(4-Arylthiazol-2-yl)hydrazineylidene)-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2-ones as Factor Xa and Factor XIa Inhibitors"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9859-6476","authenticated-orcid":false,"given":"Anna A.","family":"Skoptsova","sequence":"first","affiliation":[{"name":"Department of Organic Chemistry, Faculty of Chemistry, Voronezh State University, 1 Universitetskaya Sq., 394018 Voronezh, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9894-7777","authenticated-orcid":false,"given":"Athina","family":"Geronikaki","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8587-2710","authenticated-orcid":false,"given":"Anthi","family":"Petrou","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8167-6093","authenticated-orcid":false,"given":"Nadezhda P.","family":"Novichikhina","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Faculty of Chemistry, Voronezh State University, 1 Universitetskaya Sq., 394018 Voronezh, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8013-1112","authenticated-orcid":false,"given":"Nadezhda A.","family":"Podoplelova","sequence":"additional","affiliation":[{"name":"Center for Theoretical Problems of Physicochemical Pharmakology, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5623-723X","authenticated-orcid":false,"given":"Georgii A.","family":"Bykov","sequence":"additional","affiliation":[{"name":"Center for Theoretical Problems of Physicochemical Pharmakology, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6459-1511","authenticated-orcid":false,"given":"Aleksandr A.","family":"Anis\u2019kov","sequence":"additional","affiliation":[{"name":"R&D Department, VIC Animal Health, VIC Group, 308570 Belgorod, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2821-6252","authenticated-orcid":false,"given":"Svetlana A.","family":"Soloveva","sequence":"additional","affiliation":[{"name":"Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 119334 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6576-0305","authenticated-orcid":false,"given":"Khidmet S.","family":"Shikhaliev","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Faculty of Chemistry, Voronezh State University, 1 Universitetskaya Sq., 394018 Voronezh, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.2515","article-title":"Arterial Thrombosis\u2014Insidious, Unpredictable and Deadly","volume":"17","author":"Jackson","year":"2011","journal-title":"Nat. Med."},{"key":"ref_2","unstructured":"Chackalamannil, S., Ward, S.E., and Rotella, D. (2017). Advances in Anticoagulants. Comprehensive Medicinal Chemistry III, Elsevier."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/ehjcvp\/pvad076","article-title":"Factor XIa Inhibitors: Collecting the Clinical Evidence","volume":"10","author":"Lewis","year":"2024","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ejmech.2016.05.039","article-title":"Contemporary Developments in the Discovery of Selective Factor Xa Inhibitors: A Review","volume":"121","author":"Patel","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","article-title":"Rivaroxaban Compared with Standard Anticoagulants for the Treatment of Acute Venous Thromboembolism in Children: A Randomised, Controlled, Phase 3 Trial","volume":"7","author":"Male","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","article-title":"Safety and Efficacy of Factor XIa Inhibition with Milvexian for Secondary Stroke Prevention (AXIOMATIC-SSP): A Phase 2, International, Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Trial","volume":"23","author":"Sharma","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/med.21503","article-title":"Recent Advances in the Discovery and Development of Factor XI\/XIa Inhibitors","volume":"38","author":"Afosah","year":"2018","journal-title":"Med. Res. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1538-7836.2009.03395.x","article-title":"Factor XI deficiency in humans","volume":"7","author":"Seligsohn","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1046\/j.1538-7836.2003.00195.x","article-title":"Inherited factor XI deficiency confers no protection against acute myocardial infarction","volume":"1","author":"Salomon","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.1538-7836.2007.02446.x","article-title":"The Intrinsic Pathway of Coagulation: A Target for Treating Thromboembolic Disease?","volume":"5","author":"Gailani","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1021\/acsptsci.3c00052","article-title":"Determination of the Potential Clinical Benefits of Small Molecule Factor XIa Inhibitors in Arterial Thrombosis","volume":"6","author":"Wichaiyo","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.4155\/fmc-2015-0020","article-title":"Structure\u2013Activity Relationship Studies for Multitarget Antithrombotic Drugs","volume":"8","author":"Neves","year":"2016","journal-title":"Future Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"29770","DOI":"10.1074\/jbc.M805214200","article-title":"Kinetic Characterization of the Protein Z-Dependent Protease Inhibitor Reaction with Blood Coagulation Factor Xa","volume":"283","author":"Huang","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.febslet.2009.05.009","article-title":"An Anticoagulant Peptide from the Human Hookworm, Ancylostoma duodenale That Inhibits Coagulation Factors Xa and XIa","volume":"583","author":"Gan","year":"2009","journal-title":"FEBS Lett."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ijpara.2015.03.009","article-title":"Conserved Amblyomma americanum Tick Serpin19, an Inhibitor of Blood Clotting Factors Xa and XIa, Trypsin and Plasmin, Has Anti-Haemostatic Functions","volume":"45","author":"Kim","year":"2015","journal-title":"Int. J. Parasitol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ejmech.2016.08.039","article-title":"Hybrid Molecules: The Privileged Scaffolds for Various Pharmaceuticals","volume":"124","author":"Mishra","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1021\/jm401670x","article-title":"Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors","volume":"57","author":"Quan","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Novichikhina, N., Ilin, I., Tashchilova, A., Sulimov, A., Kutov, D., Ledenyova, I., Krysin, M., Shikhaliev, K.S., Gantseva, A., and Gantseva, E. (2020). Synthesis, Docking, and In Vitro Anticoagulant Activity Assay of Hybrid Derivatives of Pyrrolo[3,2,1-ij]quinolin-2(1H)-one as New Inhibitors of Factor Xa and Factor XIa. Molecules, 25.","DOI":"10.3390\/molecules25081889"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1134\/S1070363223140359","article-title":"Synthesis and Study of New Anticoagulant Candidates Based on 6-Aryl-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline-1,2-diones","volume":"93","author":"Skoptsova","year":"2023","journal-title":"Russ. J. Gen. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e202203981","DOI":"10.1002\/slct.202203981","article-title":"Allylic and Retro-Allylic Rearrangements upon Bromination of 8,9-Substituted 4,4,6-Trimethyl-4H-Pyrrolo[3,2,1-ij]Quinoline-1,2-Diones. New Aspects and Synthetic Applications","volume":"8","author":"Novichikhina","year":"2023","journal-title":"ChemistrySelect"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s11172-020-2834-3","article-title":"Synthesis of 4H-Pyrrolo[3,2,1-ij]quinoline-1,2-diones Containing a Piperazine Fragment and Study of Their Inhibitory Properties Against Protein Kinases","volume":"69","author":"Novichikhina","year":"2020","journal-title":"Russ. Chem. Bull."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7425","DOI":"10.1021\/acs.jmedchem.8b00173","article-title":"Factor XIa inhibitors as new anticoagulants","volume":"61","author":"Quan","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1107\/S1744309112009037","article-title":"High-resolution crystal structures of factor XIa coagulation factor in complex with nonbasic high-affinity synthetic inhibitors","volume":"68","author":"Fradera","year":"2012","journal-title":"Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Fjellstr\u00f6m, O., Akkaya, S., Beisel, H.-G., Eriksson, P.-O., Erixon, K., Gustafsson, D., Jurva, U., Kang, D., Karis, D., and Knecht, W. (2015). Creating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug design. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0113705"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1021\/acsmedchemlett.5b00066","article-title":"Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2\u2032 Moiety","volume":"6","author":"Hu","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1517\/13543776.2016.1154045","article-title":"Factor XIa Inhibitors: A Review of the Patent Literature","volume":"26","author":"Desai","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.bmcl.2014.12.050","article-title":"Pyridine and pyridinone-based factor XIa inhibitors","volume":"25","author":"Corte","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acs.jmedchem.1c00613","article-title":"Discovery of milvexian, a high-affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy","volume":"65","author":"Dilger","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1021\/acs.jmedchem.1c02153","article-title":"Targeting the S2 Subsite Enables the Structure-Based Discovery of Novel Highly Selective Factor XIa Inhibitors","volume":"65","author":"Yao","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"113437","DOI":"10.1016\/j.ejmech.2021.113437","article-title":"Design, synthesis and biological evaluation of novel FXIa inhibitors with 2-phenyl-1H-imidazole-5-carboxamide moiety as P1 fragment","volume":"220","author":"Lei","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7226","DOI":"10.1021\/acs.jmedchem.0c00464","article-title":"Discovery of a high affinity, orally bioavailable macrocyclic FXIa inhibitor with antithrombotic activity in preclinical species","volume":"63","author":"Yang","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.bmcl.2015.01.028","article-title":"Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties","volume":"25","author":"Pinto","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Wang, Y., Yuan, J., Yan, S., Liu, P., Zheng, Z., Zhang, S., Meng, F., Liu, W., Huang, C., and Wei, Q. (2024). Design, synthesis and biological evaluation of 6-chloro-quinolin-2-one derivatives as novel FXIa inhibitors. Bioorg. Med. Chem. Lett., 99.","DOI":"10.1016\/j.bmcl.2024.129610"},{"key":"ref_34","first-page":"105","article-title":"New functional derivatives 4,4,6-trimethyl-4H-pyrrolo[3,2,1-ij]quinoline-1,2-diones","volume":"46","author":"Leshcheva","year":"2003","journal-title":"Izv. vuzov. Khimiya I khim. Tekhnologia [ChemChemTech]"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Skoptsova, A.A., Geronikaki, A., Novichikhina, N.P., Sulimov, A.V., Ilin, I.S., Sulimov, V.B., Bykov, G.A., Podoplelova, N.A., Pyankov, O.V., and Shikhaliev, K.S. (2024). Design, Synthesis, and Evaluation of New Hybrid Derivatives of 5, 6-Dihydro-4 H-Pyrrolo [3, 2, 1-ij] Quinolin-2 (1 H)-One as Potential Dual Inhibitors of Blood Coagulation Factors Xa and XIa. Molecules, 29.","DOI":"10.3390\/molecules29020373"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"112752","DOI":"10.1016\/j.ejmech.2020.112752","article-title":"Novel 2-indolinone thiazole hybrids as sunitinib analogues: Design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity","volume":"208","author":"Mahmoud","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ejmech.2015.02.032","article-title":"(3Z)-3-(2-[4-(aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptase","volume":"93","author":"Meleddu","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00044-018-2136-6","article-title":"Synthesis, molecular docking, ctDNA interaction, DFT calculation and evaluation of antiproliferative and anti-Toxoplasma gondii activities of 2,4-diaminotriazine-thiazole derivatives","volume":"27","author":"Anusiak","year":"2018","journal-title":"Med. Chem. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"136667","DOI":"10.1016\/j.chemosphere.2022.136667","article-title":"SiO2-supported HClO4 catalyzed synthesis of (Z)-thiazolylhydrazonoindolin-2-ones and their electrochemical properties","volume":"309","author":"Shaik","year":"2022","journal-title":"Chemosphere"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"127261","DOI":"10.1016\/j.molstruc.2019.127261","article-title":"Synthesis, Cytotoxic Activity and Quantum Chemical Calculations of New 7-Thioxopyrazolo[1,5-f]Pyrimidin-2-one Derivatives","volume":"1202","author":"Saracoglu","year":"2020","journal-title":"J. Mol. Struct."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"133573","DOI":"10.1016\/j.molstruc.2022.133573","article-title":"Computer-Aided Molecular Design, Synthesis and Evaluation of Antifungal Activity of Heterocyclic Compounds","volume":"1267","author":"Oliveira","year":"2022","journal-title":"J. Mol. Struct."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2100481","DOI":"10.1002\/ardp.202100481","article-title":"Isatin Thiazoles as Antidiabetic: Synthesis, In Vitro Enzyme Inhibitory Activities, Kinetics, and In Silico Studies","volume":"355","author":"Solangi","year":"2022","journal-title":"Arch. Pharm."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Fayed, E.A., Ragab, A., Eldin, R.R.E., Bayoumi, A.H., and Ammar, Y.A. (2021). In Vivo Screening and Toxicity Studies of Indolinone Incorporated Thiosemicarbazone, Thiazole and Piperidinosulfonyl Moieties as Anticonvulsant Agents. Bioorg. Chem., 116.","DOI":"10.1016\/j.bioorg.2021.105300"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.2174\/0115680266256102230922101939","article-title":"Current pharmaceutical research on the significant pharmacophore mannich bases in drug design","volume":"23","author":"Yamali","year":"2023","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_45","unstructured":"(2021). CrysAlisPro, Rigaku Oxford Diffraction. Version 1.171.41.106a."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1107\/S0021889808042726","article-title":"OLEX2: A Complete Structure Solution, Refinement and Analysis Program","volume":"42","author":"Dolomanov","year":"2009","journal-title":"J. Appl. Crystallogr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1107\/S2053273314026370","article-title":"SHELXT\u2014Integrated Space-Group and Crystal-Structure Determination","volume":"A71","author":"Sheldrick","year":"2015","journal-title":"Acta Crystallogr. Sect. A Found. Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1107\/S2053229614024218","article-title":"Crystal Structure Refinement with SHELXL","volume":"C71","author":"Sheldrick","year":"2015","journal-title":"Acta Crystallogr. Sect. C Struct. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B","article-title":"Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function","volume":"19","author":"Morris","year":"1998","journal-title":"J. Comput. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1021\/ci049885e","article-title":"LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters","volume":"45","author":"Wolber","year":"2005","journal-title":"J. Chem. Inf. Model."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/17\/3544\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:35:44Z","timestamp":1760034944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/17\/3544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":51,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["molecules30173544"],"URL":"https:\/\/doi.org\/10.3390\/molecules30173544","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]}}}